Clinical Trial Update: A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) [Phase 3]

View source ↗

Summary

This clinical trial update summarizes a Phase 3 study evaluating remission-induction therapy followed by a risk-oriented postremission strategy for adults with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Northern Italy Leukemia Group | Conditions: Acute Myelogenous Leukemia | Phase 3 | Status: COMPLETED